Article in Pflugers Archiv : European journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Anna PetzendorferMedical Cell Biology, University of Regensburg, Universitätsstraβe 31, D-93053, Regensburg, Germany.
Minh Linh TranMedical Cell Biology, University of Regensburg, Universitätsstraβe 31, D-93053, Regensburg, Germany.
Bettina FirmkeInstitute of Physiology, Physiology I, University of Regensburg, Universitätstr. 31, D- 93053, Regensburg, Germany.ORCID http://orcid.org/0009-0006-5960-8231
Anja SüßMedical Cell Biology, University of Regensburg, Universitätsstraβe 31, D-93053, Regensburg, Germany.
Katharina Anna-Elisabeth BroekerInstitute of Physiology, Physiology I, University of Regensburg, Universitätstr. 31, D- 93053, Regensburg, Germany.ORCID http://orcid.org/0000-0001-5937-6756
Anna-Lena ForstMedical Cell Biology, University of Regensburg, Universitätsstraβe 31, D-93053, Regensburg, Germany. anna-lena.forst@ur.de.ORCID http://orcid.org/0000-0002-8569-8588
Funding
Central Hub for Kidney Precision MedicineU24DK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$21.1M
KPMP Kidney Mapping and Atlas Project (KMAP)U01DK133090 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$10.4M
Integrated spatial interrogation of cellular and molecular signatures of human kidney diseaseU01DK114923 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Tarek Maurice Ashkar, Pierre C Dagher · 2022 to 2026
$5.4M
Single cell multiomic and spatial atlas of acute and chronic kidney injuryU01DK114933 · NIDDK · WASHINGTON UNIVERSITY · PI Sanjay Jain · 2022 to 2026
$5.0M
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney DiseaseU01DK114920 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Christopher R Anderton, Kumar Sharma · 2022 to 2026
$3.9M
Boston Chronic Kidney Disease Research Biopsy CenterU01DK133092 · NIDDK · BOSTON MEDICAL CENTER · PI Sylvia E Rosas, Sushrut S. Waikar · 2022 to 2026
$3.5M
Multimodal Imaging Mass Spectrometry and Spatial Omics for the Human KidneyU01DK133766 · NIDDK · VANDERBILT UNIVERSITY · PI Jeffrey M Spraggins · 2022 to 2026
$3.4M
PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE)U01DK114907 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nir Hacohen, Jeffrey Benton Hodgin · 2022 to 2026
$3.2M
University of Illinois at Chicago KPMP CKD Recruitment SiteU01DK133081 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JAMES P. LASH, Ana Catherine Ricardo · 2022 to 2026
$2.7M
AKI Matched Phenotype Linked Evaluation with Tissue (AMPLE-Tissue)U01DK114866 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Chirag R Parikh · 2022 to 2026
$2.6M
Cleveland Precision Medicine Chronic Kidney Disease CohortU01DK114908 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI JOHN F. O'TOOLE, EMILIO DANIEL POGGIO · 2022 to 2026
$2.2M
Geographic and Environmental Representation in Kidney Precision MedicineU01DK133095 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Frank C Brosius, Amy Mottl · 2022 to 2026
Chronic kidney disease (CKD) affects over 850 million people worldwide and is characterized by progressive renal fibrosis driven by activated interstitial fibroblasts. Signaling by extracellular nucleotides and P2 receptors plays an important role in renal pathophysiology, yet its contribution to fibroblast activation and fibrosis remains poorly understood. Here, we investigated the expression and function of G
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Inhibition of (interstitial) P2Y · full record | Socratic